Outgoing President’s Message

Tom Kawabata

The immunotoxicology sessions at the SOT meetings were a great success. Thank you to all the people who proposed and chaired the CE courses, symposia, roundtables and workshops. The specialty section greatly appreciates your time and leadership. I also want to thank the contributors towards the 2005 meeting program.

I hope you were able to catch-up with old friends and meet new people at our mixer/business meeting. I want to thank Gary Burleson for his annual contribution of the Fundamental Immunology textbook and Taylor and Francis for their contribution for the cash award for the best student and post-doc presentation. Also many thanks to Kathy Sarlo, Frank Gerberick and Danuta Herzyk for their contributions of gift baskets for the survey raffle. I look forward to continue working with you and the ISS officers in addressing our specialty section goals.

Tom

Important Deadline

The Immunotoxicology Specialty Section Logo Contest

Logos need to be submitted by Friday, July 2nd. See Contest Rules on Page 6.
In coming President's Message

Bob Luebke

First of all, thanks for the opportunity to serve as an officer in the Specialty Section. It has been a great experience so far, and this year should be no exception.

This last year was a good one for our Section. Membership increased by more than one third and there was an impressive increase in student/post doc members, from 5 previous year to 31 this year. Welcome to everyone who is new to the specialty section and welcome back to those who rejoined. Thanks also to the mentors who encouraged students to join and to the students who chose this section. (Mentors and Students please note: SOT is changing the application process so that only one sponsor is required on a student membership application, easing the process somewhat.) We were well represented at the meeting in Baltimore; immunotox-related sessions were presented every morning and afternoon, beginning with a CE course on flow cytometry that was presented twice on Sunday and ending with a poster session on Thursday morning. Many thanks to all of you who were involved in organizing and presenting sessions this year, to everyone who took the time to prepare and present talks and posters and to the members of the Program Committee for the 2004 meeting.

Special thanks to Tom Kawabata for the excellent job he did last year as President. The results of Tom’s membership survey are a real asset to the Executive Committee and will help us plan for the coming years. One direct effect of the survey was the shortest business session in recent memory in Baltimore. Please let your feelings be know about how time was spent at the Specialty Section meeting, and we will do our best to honor the preferences of the membership at the meeting next year.

Over the years the Specialty Section has been fortunate to have dedicated individuals serving on the Executive Committee as elected officers and committee chairs, but the Committee can always use new ideas and fresh perspectives. Membership input is crucial to our continued success, and if you have ideas for improvement or are interested in serving is some capacity in the Section, please let us know. Serving on a committee or as an elected officer does take a little bit of time, but is certainly not a drudgery. In truth, it is probably more fun than serving on those committees associated with your real job. Members of the Executive Committee are listed on the Immunotoxicology Specialty Section web page (http://www.toxicology.org/MemberServices/SpecSection/immunotox/Index.html) and on the mast head and committee reports in this Newsletter. My email address is luebke.robert@epa.gov, and my phone number is 919.541.3672. New ideas often come from new members, so don’t be shy just because you are a student, post doc or new member. You don’t have to be a long-term member of the Section to contribute or to serve on committees or hold office. Please remember that next March when the committee signup sheets are passed around at the business meeting.

Most of you are aware of changes NIH has made in the composition of study sections. These changes could have an adverse effect on funding for toxicology-based research, something that could directly and indirectly affect many of us. This issue is currently before the SOT Council as a high priority item. Steve Pruett has also been heading an ad hoc group of Immunotox Section members that are considering possible responses to NIH. Look for a status report from him in the next Newsletter.

It is not too early to be thinking about nominations for Section awards or for next year’s slate of officers. Nomination deadlines are months away, but have a way of sneaking up on us all. The Specialty Section awards, criteria for each award and contact information are all available on the Immunotoxicology Specialty Section page. A link for the page is located on the SOT web page. Speaking of the SOT web page, Headquarters is in the process of revamping the web site. If you have an idea for improvements, contact Peyton Myers (LMyers@cdc.gov), Chair of the Immunotox Communications Committee or me, or send your ideas directly to Debbie O’Keefe (debbie@toxicology.org) at SOT headquarters.

Faculty of the CE Class, Functional Flow Cytometry, L to R: Carl Bortner, LeighAnn Burns-Naas, Scott Burchiel, Nancy Kerkvliet, Debra Laskin (not shown)
The Awards Committee Chaired by Paige Lawrence presented the following awards:

Best Submission by a Postdoctoral Fellow, the winner is Dr. Lucy A. Gildea.  (no picture available)

Best Submission by a Graduate Student, Jacintha Shenton.

Best Paper Award:  
(no picture available)

Outstanding Young Investigator Award, Dr. Dori Germolec.

A Committee Chaired by Bob Luebke (Vice President) presented the following Award: Young Investigator Awardee Dori: Pictured L to R are Dave Sherr, Mike Luster, Dori Germolec (winner of the Outstanding Young Investigator Award), and Nancy Kerkvliet

SOT Immunotoxicology Specialty Section Membership By Membership Category

George DeGeorge presented a thorough and encouraging report from the Membership Committee.

### 2003

- Total = 220
- Full: 77%
- Assoc: 3%
- Student: 20%

### 2004

- Total = 297
- Full: 69%
- Assoc: 21%
- Student: 10%

By Organization Category 2004

- 51% Industry
- 33% Academia
- 12% Government
- 2% Other
- 2% Consulting
Student and Post-doc Activities

Dear fellow immunotox students,

The ISS-SOT student events (mixer and mentor dinner) in Baltimore were a success. We had the student mixer at the Wharf Rat Brewery and potentially recruited some new ISS members. However, the turnout of already existing members was low and we would like to remind you that these mixer events offer us an opportunity to socialize as well as to foster future working relationships with our fellow colleagues. One of our success stories is exemplified by a scientific collaboration that occurred between 2 immunotoxicology Ph.D. students initiated at the Salt Lake City 2003 ISS events; this collaboration was fruitful and has produced a manuscript. Therefore, as your rep, I urge you to take advantage of ISS sponsored events to network. In an effort to better improve our events for the next SOT meeting, I am asking you to email me with any feedback on what would increase your attendance to our events.

I would like to thank all those who participated in the ISS mentor-student dinner. We had a nice mix of academia and industry mentors which allowed students and post-docs to ask questions about career development as well as advice on how best to network and job hunt. I would like to focus next year’s mentor dinner on interviewing skills and what mentors look for during an interview. If there are any career topics that you feel we have not addressed at the ISS, please let me know and I will make it a priority for next year’s meeting.

Lastly, in the following months, I will be contacting students and post-docs directly via email inviting you to our second teleconference on careers in immunotoxicology and I look forward to your participation.

Sincerely,

Beatrice Seguin
ISS student rep.
beatrice.seguin@utoronto.ca
Program Committee:
Chair-(Vice President)-Mitch Cohen (Vice President-Elect, cohenm@env.med.nyu.edu)
Past chair: Ken Hastings
Greg Ladics
Yanli Ouyang
LeighAnn Burns-Naas
Peyton Myers
Michael Woolhiser
Dori Germolec
Ian Kimber
Mitzi Nagarkatti
Susan McKarns
Shannon Doherty

Education Committee:
Chair-Judy Zelikoff (Judyz@env.med.nyu.edu)
Castle Funatake
Petia Simeonova
MaryJane Selgrade

Regulatory Committee:
Chair-Ken Hastings (hastingsk@cdrer.fda.gov)
Yanli Ouyang
Peyton Myers
Karen Price

Membership Committee:
Chair-George DeGeorge (GeoDG@aol.com)
Pamela Hebert
Jessica Duffy
Marsha Ward

Awards Committee:
Chair (Senior Councilor)-Jeanine Bussiere (bussiere@gene.com)
Mike McCabe
Prakash Nagarkatti
Michael Whitekus
Tai L. Guo
Pamela Hebert
Lisa Ryan
Ian Kimber
Helen Haggerty

Communications Committee:
Chair: Peyton Myers (lmyers@cdc.gov)
Mitch Cohen
Deborah Keil
Margie Peden-Adams
Elizabeth Varcza
Michael Whitekus

IMMUNOTOXICOLOGY SPECIALTY SECTION COMMITTEES: 2004-2005

September 13-15, Silverado Resort, Napa CA

Two co-located meetings are offered, entitled “Biotechnology-Derived Therapeutics: Pharmacology and Toxicology Perspectives in Nonclinical Development” (9/13-14) and “Pharmaceuticals and Immunomodulation” (9/15). Registration is online at www.criver.com (under “Meetings”), or by contacting Gayla Ouellette at gouellette@sbi.criver.com or Lauren Black, at lblack@sbi.criver.com

The “Pharmaceutics and Immunomodulation” meeting was introduced last year, to recognize the convergence between immunotoxicology and drug risk assessment. Many new biotech drugs, as well as transplant drugs, are targeted immunotoxins with animal and clinical history.

Cross species predictive value, clinical relevance of animal models, and new primate methods are key aspects of talks and planned discussions. Discussion questions will be premailed to early registrants; a key aim of this meeting is publication of consensus views. The “Biotech Symposium” has been held annually for 8 years, and features specific case presentations on biotech drugs in current and recent development, focusing on preclinical toxicology interpretation and regulatory challenges.
The Immunotoxicology Specialty Section is looking for a logo. In order to find an interesting, exciting, stimulating, and all around COOL logo, the ISS is hosting a contest for the best logo. The logo will be used in association with the ISS website and possibly other ISS communications. A cash prize of 50$ (US) has been allotted for the winner.

How the submitted logo should look:

- Logos should adequately represent the Immunotoxicology Specialty Section.
- The name “Immunotoxicology Specialty Section” or an acronym for it (ISS, ImToxSS, ImTox, etc.) should appear somewhere in the logo.
- The logo may be used in different formats. The actual size will depend on the logo.
- A suggested size would be no wider than 150 pixels, and no smaller than 80 pixels.
- If possible, the artwork should be vector based or have a minimum resolution of at least 300 dpi to make sure the art will reproduce well in print as well as on the web.
- Color images are preferred, but black and white images will also be accepted.

Contributing your logo:

- ISS members may submit as many logos to the contest as they want.
- Contributed logos will be posted onto the ISS website for viewing and voting.
- Logos not created by the submitter or logos with illegal, discriminating or otherwise offensive contents, can not be accepted.
- Submit logos to Peyton Myers (LMyers@cdc.gov).
- Logos should be received by Friday, July 2, 2004.

Copyrights and License:

- After submission, the author may retain copyright rights to the logo but agree to free, unrestricted use of the logo by the Immunotoxicology Specialty Section.

Voting:

- In the election phase (July 9 - July 30), ISS members can go to the ISS website and vote for their favorite logo.
- One vote (via email) per person can be sent to Peyton Myers (LMyers@cdc.gov).
- The logo with the most votes wins.
- All ISS members (full, associate, post-doc, and student) can vote.
- All votes must be submitted by Friday, July 30, 2004.

The Prize!!! - Cash, Money, Dough, Moolah, $$$$$$

- The prize for the contest is 50$ (US dollars).
CALL FOR PAPERS

New Taylor and Francis Journal for 2004

Please submit papers to:

Mitchell D. Cohen, PhD
Editor-in-Chief, Journal of Immunotoxicology
New York University School of Medicine
Nelson Institute School of Medicine
57 Old Forge Road, Tuxedo, NY 10987 USA
cobenn@env.med.nyu.edu

Associate Editors

Donald E. Gardner, PhD/ATS Fellow, Inhalation Toxicology Associates
Kenneth L. Hastings, Dr.P.H./DABT, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Robert V. House, PhD, Dynport Vaccine Company LLC
Robert W. Lauebke, PhD, National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency
Jean F. Regal, PhD, Department of Pharmacology, University of Minnesota
Kazuchiri Nakamura, DVM, PhD, Shionogi & Co., Ltd., Japan
Joseph G. Vos, DVM, PhD, National Institute of Public Health and the Environment (RIVM), the Netherlands

Visit Our Website: www.taylorandfrancis.com
Sign Up For Your FREE Sample Copy or Subscribe at a Special SOT Member Rate Today!

The Journal of Immunotoxicology is a peer-reviewed journal that provides a needed singular forum for the international community of immunotoxicologists, immunologists, and toxicologists working in academia, government, consulting, and industry to both publish their original research and be made aware of the research findings of their colleagues in a timely manner. Research from many subdisciplines is presented in the journal, including the areas of molecular, developmental, pulmonary, regulatory, nutritional, mechanistic, wildlife, and environmental immunotoxicology, immunology, and toxicology. Original research articles as well as timely comprehensive reviews are published.

The first issue of Journal of Immunotoxicology appeared March 2004 and included the following articles:

"Ultraviolet Light and Resistance to Infectious Diseases" - Annemarie Sijtters, Johan Garssen, Joseph G. Vos, and Henk van Loveren

"Suppression of Immune Function and Susceptibility to Infections in Humans: Association of Immune Function with Clinical Disease" - Bob Lauebke, Christine Parks, and Mike Luster

"Immunologic Effector Mechanisms in Animal Models of Occupational Asthma" - Jean F. Regal

"Pulmonary Immunotoxicology of Select Metals: Aluminum, Arsenic, Cadmium, Chromium, Copper, Manganese, Nickel, Vanadium, and Zinc" - Mitchell D. Cohen

To Order

Journal of Immunotoxicology
Print ISSN: 1547-691X Online ISSN: 1547-6901
Institutional print subscription at US$995/£523*
Personal print subscription at US$165/£85
Special SOT member print subscription at US$65/£33*
*Institutional and SOT subscriptions include free online access

Contact:
Taylor & Francis
Attn: Mary Drabot
835 Chestnut Street
Philadelphia, PA 19106
Tel: (215) 625-8800 ext. 242
Fax: (215) 625-5946
E-mail: mary.drabot@taylorandfrancis.com
ANYTIME you have a new publication to report, please send it to hratajcaz@rdg.boehringer-ingelheim.com
It will be included in the next newsletter.

ASTHMA, ALLERGY AND HYPERSENSITIVITY


Dong, W, Selgrade MJK, and Gilmour, MI. Systemic administration of B pertussis enhances pulmonary sensitization to hour dust mite in juvenile rats. Toxicological Sciences, 72:113-121, 2003.


Neff-LaFord HD, Vorderstrasse BA, Lawrence BP. Fewer CTL, not enhanced NK cells, are sufficient for viral clearance form the lungs of immunocompromised mice. Cell Immunol 226: 54-64, 2004.


AUTISM


Reviews


CYTOKINES AND CHEMOKINES


EFFECTS: COMPOUNDS

Abernethy DJ, Kleymenova EV, Rose J, Recio L, Faiola B. Human CD34+ hematopoietic progenitor cells are sensitive targets for toxicity induced by 1,4-Benzooquinone. Toxicol Sci 79: 82-89, 2004.


**EFFECTS: ENVIRONMENT**


**GENETICS AND IMMUNOLOGY**


MODELS AND METHODS


GENERAL IMMUNOTOXICOLOGY


Neff-LaFord HD, Vorderstrasse BA, Lawrence BP. Fewer CTL, not enhanced NK cells, are sufficient for viral clearance from the lungs of immunocompromised mice. Cell Immunol 226: 54-64, 2004.


